Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathy [0.03%]
利福昔明可降低肝硬化合并显著性肝性脑病患者的再住院风险
Arun B Jesudian,Patrick Gagnon-Sanschagrin,Rebecca Bungay et al.
Arun B Jesudian et al.
Background: Rifaximin treatment is associated with reduced rates of overt hepatic encephalopathy (OHE) hospitalization relative to lactulose alone. This real-world study evaluated the impact of treatment on rehospitalizat...
Hyperammonemia predicts the development of liver-related events in a prospective cohort of stable cirrhosis patients and the external validation of the AMMON-OHE score [0.03%]
血氨水平可预测失代偿期肝硬化患者的肝相关事件：一项前瞻性队列研究及AMMON-OHE评分的外部验证
Loi Pooi Ling,Xuan Han Koh,Daniel Lim Yan Zheng et al.
Loi Pooi Ling et al.
Background: Predicting liver-related events (LREs) in stable cirrhosis is crucial; however, traditional scoring methods perform poorly. Ammonia, due to its pathophysiological integration, may prognosticate LRE. This study...
A liver function test pathway significantly increases the early detection of chronic liver disease and cirrhosis [0.03%]
一种肝功能检查路径可显著增加慢性肝病和肝硬化早期检测率
Jingwei Gao,Haroon Ahmed,Rebecca Cannings-John et al.
Jingwei Gao et al.
Background: To enhance early liver disease detection, a clinical pathway integrating reflex AST testing and automated AAR reporting was implemented. We aim to evaluate the long-term effectiveness of introducing reflex AST...
MAPK15 controls intracellular lipid uptake and protects mammalian liver from steatotic disease [0.03%]
MAPK15调节胞内脂质摄取并保护哺乳动物肝脏免于脂肪变性疾病
Giovanni Inzalaco,Sara Gargiulo,Denise Bonente et al.
Giovanni Inzalaco et al.
Background: Accumulation of lipids in the liver characterizes metabolic dysfunction-associated steatotic liver disease (MASLD), the most prevalent chronic liver disease worldwide. ...
Differential survival benefit of curative versus non-curative intent treatment in a real-world cohort with early and intermediate-stage hepatocellular carcinoma [0.03%]
基于真实世界队列的早期和中期肝细胞癌治愈性与非治愈性治疗预后差异分析
David Goldberg,Binu John,David Kaplan et al.
David Goldberg et al.
Background: Treatment algorithms for hepatocellular carcinoma (HCC) account for tumor burden/stage and severity of liver disease. There are conflicting data on the differential benefit of curative versus non-curative trea...
Comparative Study
Hepatology communications. 2026 Jan 29;10(2):e0891. DOI:10.1097/HC9.0000000000000891 2026
Liver iron levels are associated with HFE-hemochromatosis genotype, diet, adiposity, and disease in the UK Biobank [0.03%]
英国生物样本库中肝脏铁水平与HFE-遗传性血色病基因型、饮食、肥胖度和疾病的关系研究
Mitchell R Lucas,Luke C Pilling,João Delgado et al.
Mitchell R Lucas et al.
Introduction: HFE genetic variants, especially C282Y homozygosity (C282Y+/+), can increase systemic iron and cause hemochromatosis, though expression varies. Excess iron can lead to liver disease and liver cancer, yet fac...
The role of the hepatologist in the alcohol-associated liver disease epidemic [0.03%]
酒精相关性肝病流行中的肝病学家作用
Gonzalo Gómez Perdiguero,Luis Antonio Díaz,Sebastián Marciano
Gonzalo Gómez Perdiguero
Hepatocyte-hepatic stellate cell interactions in liver fibrosis: Mechanisms and therapeutic implications [0.03%]
肝纤维化中肝细胞-库普弗细胞相互作用的机制及治疗意义
Zihan Wang,Zixuan Cao,Yunsheng Dong et al.
Zihan Wang et al.
Hepatic fibrosis, driven by chronic liver injury, results from complex interactions between hepatocytes and hepatic stellate cells (HSCs). In response to hepatocyte damage, activated HSCs undergo transdifferentiation into myofibroblast-like...
ROTEM-detected hypocoagulability is associated with major non-portal hypertensive bleeding in cirrhosis [0.03%]
ROTEm检测的低凝状态与失代偿期肝硬化患者非门脉高压症出血的相关性研究
Kymentie Ferdinande,Jochen Decaestecker,Charlotte De Vloo et al.
Kymentie Ferdinande et al.
Background: Patients with acute-on-chronic liver failure (ACLF) display preserved thrombin generation (TG) but hypocoagulable profiles on rotational thromboelastometry (ROTEM). The relationship with non-portal hypertensiv...
Novel biomarkers for early detection of HCC in patients with MASLD or ALD [0.03%]
用于MASLD或ALD患者早期检测HCC的新型生物标志物
Sneha Deodhar,Mohammad Jarrah,Neehar D Parikh et al.
Sneha Deodhar et al.